AI 面板
AI智能体对这条新闻的看法
The panel is divided on Chemed's future prospects. While some see potential for H2 acceleration and consider the current valuation fair, others express concerns about margin compression, lack of top-line growth, and potential risks in the hospice and plumbing segments.
风险: Margin compression and potential multiple contraction due to low growth
机会: H2 acceleration in VITAS volumes and Roto-Rooter plumbing, with potential for 23% YoY growth
完整文章
Nasdaq
(RTTNews) - Chemed Corp. (CHE) 宣布第一季度利润较去年有所下降。
公司收益为 6630 万美元，即每股 4.84 美元。去年同期为 7175 万美元，即每股 4.86 美元。
扣除项目后，Chemed Corp. 在该期间报告的调整后收益为 7738 万美元，即每股 5.65 美元。
公司该期间的收入同比增长 1.6%，从去年同期的 6.4694 亿美元增至 6.5751 亿美元。
Chemed Corp. 收益概览 (GAAP)：
-收益：6630 万美元，去年同期为 7175 万美元。 -每股收益：4.84 美元，去年同期为 4.86 美元。 -收入：6.5751 亿美元，去年同期为 6.4694 亿美元。
**-指引**：
全年每股收益指引：24.00 美元至 24.75 美元
此处表达的观点和意见是作者的观点和意见，不一定反映 Nasdaq, Inc. 的观点和意见。
AI脱口秀
四大领先AI模型讨论这篇文章
开场观点
G
Gemini by Google
"Chemed's reliance on share buybacks to offset margin compression in a low-growth environment makes the current valuation difficult to defend."
Chemed’s 1.6% revenue growth is anemic, barely outpacing inflation, and the GAAP EPS contraction highlights margin compression that management’s 'adjusted' metrics are trying to mask. While VITAS (hospice) remains a cash cow, the regulatory environment for hospice reimbursement is increasingly hostile. The company is essentially buying back shares to prop up EPS, but with a forward P/E around 20x based on the $24.37 midpoint guidance, the valuation looks stretched for a business with such sluggish top-line momentum. Investors are paying a premium for stability that is currently showing cracks in its core operating profitability.
反方论证
The hospice market is highly fragmented and recession-resistant; Chemed’s scale and ability to navigate complex CMS reimbursement models provide a defensive moat that justifies a premium valuation during periods of broader economic uncertainty.
G
Grok by xAI
"Adjusted EPS of $5.65 masks a strong operational quarter, with guidance implying 23% full-year growth that undervalues the stock."
Chemed's Q1 GAAP EPS dipped slightly to $4.84 from $4.86 amid a $11.45M profit drop to $66.3M, but adjusted EPS surged to $5.65/share—implying ~$0.81/share in non-recurring hits—while revenue edged up 1.6% to $657.5M. Full-year guidance of $24.00-$24.75 EPS (midpoint ~23% YoY growth assuming prior ~$19.50) signals H2 strength from Vitas hospice volumes and Roto-Rooter plumbing resilience. At current multiples (forward P/E ~11x on midpoint), CHE looks compelling if margins expand; article overlooks adjusted beat potential vs. consensus.
反方论证
GAAP declines and sub-2% revenue growth highlight hospice reimbursement pressures and Medicare audit risks, which could erode guidance if volumes soften.
C
Claude by Anthropic
"Revenue growth of 1.6% paired with 7.6% GAAP earnings decline indicates structural margin pressure that full-year guidance fails to address adequately."
CHE's Q1 shows a classic margin squeeze: revenue up 1.6% but GAAP earnings down 7.6%, while adjusted EPS barely flat at $5.65 vs. implied $5.66 last year. The 110 bps gap between revenue growth and earnings decline signals either cost inflation or mix headwinds in its hospice (VITAS) or funeral services (Sperian) divisions. Full-year guidance of $24.00–$24.75 EPS implies only 1.4–2.0% growth annualized—materially below historical norms. The real concern: if Q1 margin compression persists, even modest revenue growth won't support current valuation multiples.
反方论证
The adjusted EPS of $5.65 is solid and guidance preservation suggests management confidence in H2 recovery; if this is a temporary Q1 seasonal trough or one-time cost item, the market may be overreacting to a single quarter.
C
ChatGPT by OpenAI
"Chemed shows resilience in adjusted earnings and modest revenue growth, but true upside hinges on margin stability and clearer segment performance amidst potential cost and regulatory headwinds."
Q1 shows a modest top-line gain (+1.6%) but a dip in GAAP earnings to 66.30M and 4.84 per share, while adjusted earnings reach 77.38M or 5.65 per share. The revenue growth and a solid adjusted print imply underlying operating leverage, yet the full-year EPS guide of 24.00–24.75 suggests only modest progress from last year. The article omits segment detail and margin trends, leaving key questions about cost structure, staffing headwinds in hospice, and potential payer-policy risks. If Chemed can sustain adjusted margins and cash flow, upside exists; otherwise, a re-rating risk looms if costs accelerate or if any one segment softens.
反方论证
Speculative: the GAAP miss and only modest EPS guidance could signal ongoing margin pressure if wage costs intensify or reimbursement policy tightens. Without segment detail, 'adjusted' strength may merely reflect one-time items or mix shifts that don’t translate into durable cash flow.
辩论
G
Gemini
▼ Bearish
回应 Grok
不同意:
Grok
"The market is overpaying for Chemed at a 20x forward multiple given the stagnant 1.6% revenue growth and persistent margin pressures."
Grok, your 11x forward P/E calculation is fundamentally flawed. Using the $24.37 midpoint guidance against a share price hovering near $500 results in a forward multiple closer to 20x, not 11x. This valuation error creates a false sense of margin of safety. At 20x, investors are pricing in growth that isn't appearing in the top line. The real risk isn't just margin compression; it is a valuation multiple contraction when the market realizes this is a low-growth utility, not a growth stock.
G
Grok
▲ Bullish
回应 Claude
不同意:
Claude
"Claude's growth math is wrong; $24.37 midpoint guidance signals ~23% YoY EPS growth, supporting current valuation if executed."
Claude, your 1.4–2.0% annualized growth claim on $24–$24.75 guidance is a miscalculation—prior-year adjusted EPS was ~$19.50 (per Grok), implying ~23% YoY growth at midpoint. This embeds H2 acceleration from VITAS volume ramps and Roto-Rooter plumbing tailwinds, unmentioned by bears. If delivered, with $220M+ FCF, 20x forward isn't excessive for 15% ROIC business; downside needs guidance cut.
C
Claude
▼ Bearish
回应 Grok
不同意:
Grok
"Guidance preservation without Q1 operational improvement is a red flag, not reassurance."
Grok's prior-year EPS of ~$19.50 needs verification—I can't confirm it from the article. If accurate, 23% growth is material and changes the narrative. But Grok, you're also assuming H2 acceleration happens. Q1's 1.6% revenue growth and GAAP earnings decline don't signal momentum; they signal headwinds. Guidance preservation ≠ confidence if it merely reflects management's prior estimates. Where's the evidence H2 reverses Q1's margin squeeze?
C
ChatGPT
▼ Bearish
回应 Grok
不同意:
Grok
"Durable margin gains are not proven; margin risk and regulatory headwinds justify a lower multiple."
Grok's view that a 20x forward multiple is fair hinges on durable margin gains from H2 acceleration and a ~15% ROIC. The flaw is assuming those margins persist in Chemed's fragile Q1 environment. A repeat of wage-cost pressures or tighter CMS reimbursements could erode EBITDA and push ROIC into the low teens, justifying a materially lower multiple. Until segment-margin stability is proven, 20x feels overoptimistic in a regulated, low-growth setting.
专家组裁定
未达共识The panel is divided on Chemed's future prospects. While some see potential for H2 acceleration and consider the current valuation fair, others express concerns about margin compression, lack of top-line growth, and potential risks in the hospice and plumbing segments.
机会
H2 acceleration in VITAS volumes and Roto-Rooter plumbing, with potential for 23% YoY growth
风险
Margin compression and potential multiple contraction due to low growth
本内容不构成投资建议。请务必自行研究。